Nonetheless, anti-MAG titers may serve as an indirect marker of therapeutic response, particularly in the context of B-cell depleting therapies such as RTX, as they likely reflect suppression of the underlying monoclonal gammopathy. Here, MAG is linked to monoclonal gammopathy.